Skip to main content
. Author manuscript; available in PMC: 2017 Oct 12.
Published in final edited form as: Ann Surg Oncol. 2016 Feb 4;23(6):1993–2000. doi: 10.1245/s10434-016-5116-4

FIG. 5.

FIG. 5

Planned clinical trial schema. A randomized, phase II, clinical trial is being planned to evaluate the efficacy and tolerability of adjuvant sequential gemcitabine followed by trametinib for patients with resected PDAC. RD recurrent disease, SE side effects